Hepatitis A News and Research RSS Feed - Hepatitis A News and Research

Hepatitis A (formerly known as ''infectious hepatitis'') is an acute infectious disease of the liver caused by the hepatitis A virus (HAV), which is most commonly transmitted by the fecal-oral route via contaminated food or drinking water.
New text message alert system helps parents remember child's vaccination appointments

New text message alert system helps parents remember child's vaccination appointments

Nearly a third of all children nationwide and in Kentucky aren't up-to-date with the vaccination schedule recommended by the Centers for Disease Control (CDC), but not because their parents are refusing vaccines. Evidence suggests parents tend to forget appointments when children are scheduled to receive immunizations. [More]
WHO report: Access to new medicines requires transparency, collaboration

WHO report: Access to new medicines requires transparency, collaboration

As the number of new medicines introduced in Europe rises, governments are finding it increasingly difficult to afford them, according to a comprehensive study released today by the WHO Regional Office for Europe. [More]
Study: HBV exposure increases immune system maturation of infants

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B. [More]
New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness analysis led by researchers at The University of Texas MD Anderson Cancer Center. [More]
New vaccine for post exposure treatment of rabies infection enters human clinical trial

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide. [More]
HBV genotype C HBeAg seroconversion rate ‘negligible’

HBV genotype C HBeAg seroconversion rate ‘negligible’

Patients with chronic hepatitis B virus genotype C infection who are positive for hepatitis B e antigen should not delay antiviral treatment in the hope of seroconversion, Korean researchers recommend. [More]
Long-term entecavir, TDF effective in chronic HBV in real-world setting

Long-term entecavir, TDF effective in chronic HBV in real-world setting

A Turkish clinical practice study shows that entecavir and tenofovir disoproxil fumarate can effectively maintain long-term virological and biochemical responses in patients with chronic hepatitis B virus infection, both in those with and without cirrhosis. [More]
Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Hepatitis B surface antigen and hepatitis B core-related antigen levels can predict long-term response to sequential nucleos(t)ide analogue and interferon-α therapy in patients with chronic hepatitis B virus infection, research indicates. [More]
Ebola crisis increases susceptibility to measles, other vaccine-preventable illnesses

Ebola crisis increases susceptibility to measles, other vaccine-preventable illnesses

Johns Hopkins Bloomberg School of Public Health researchers say that major disruptions in the health care systems in West Africa caused by the Ebola crisis have led to significant decreases in vaccinations for childhood diseases, increasing susceptibility to measles and other vaccine-preventable illnesses. [More]
Study describes the dual role of microRNA during hepatitis C infection

Study describes the dual role of microRNA during hepatitis C infection

In the battle between a cell and a virus, either side may resort to subterfuge. Molecular messages, which control the cellular machinery both sides need, are vulnerable to interception or forgery. [More]
WHO releases first-ever guidance for chronic hepatitis B treatment

WHO releases first-ever guidance for chronic hepatitis B treatment

WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year - most of them in low- and middle-income countries. [More]
Understanding strengths and weaknesses of hepatitis C viruses

Understanding strengths and weaknesses of hepatitis C viruses

Using a specially selected library of different hepatitis C viruses, a team of researchers led by Johns Hopkins scientists has identified tiny differences in the pathogens' outer shell proteins that underpin their resistance to antibodies. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera. [More]
Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. [More]
Women for Positive Action introduces new educational tool for women living with HIV

Women for Positive Action introduces new educational tool for women living with HIV

To mark International Women's Day (March 8, 2015), Women for Positive Action has launched a practical and informative new educational tool entitled 'Hepatitis and coinfection in women living with HIV'. Led by a global, multidisciplinary group of experts, Women for Positive Action is committed to addressing the specific concerns of women living with HIV. [More]
Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers. [More]
Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

Prime Therapeutics LLC received the Pharmacy Benefit Management Institute's 2015 Rx Innovation Award today in recognition of its innovative "Specialty Drug Watch List." [More]
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

Response-guided addition of adefovir to lamivudine-based therapy not only maintains long-term viral suppression in Chinese chronic hepatitis B patients with compensated liver cirrhosis, research suggests, but also improves liver function. [More]
Advertisement
Advertisement